AbbVie (ABBV) to Acquire Landos Biopharma (LABP) for $20.42/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
Go back to AbbVie (ABBV) to Acquire Landos Biopharma (LABP) for $20.42/Share
March 25, 2024 8:30 AM EDT
- Landos lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC)
NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV) (AbbVie) and Landos Biopharma, Inc. (NASDAQ: LABP) (Landos) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family)... More
